Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569574 | 1.00 | TAAR1 (0.57) | TAAR1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2604881 | 0.85 | SLC6A2 (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL29786276 | 0.85 | SLC6A2 (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL3265767 | 0.82 | CYP2A6 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1245510 | 0.82 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22113733 | 0.82 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL14233502 | 0.82 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL23689573 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL21715696 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22060305 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | TAAR1 693/4885CFTR 350/4885SLC6A2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.